CClinicalTrials.gg
CompletedNCT05053464Updated May 23, 2022

A DCE to Understand Patients' Preferences for Alternative Models of Care

An observational study in Fibromyalgia, sponsored by University of Aberdeen. Completed at 1 site in United Kingdom. Per ClinicalTrials.gov, last updated 2022-05-23.

Sponsored by University of Aberdeen · Observational

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
41
Sex
All
01

Study summary

A pilot survey for a Discrete Choice Experience to understand the strength of patient's preferences for alternative models of care for fibromyalgia.

Read the detailed description

We will use the Discrete Choice Experiment (DCE) method to elicit preferences for alternative models of care for people with fibromyalgia. The DCE is a choice-based survey that quantifies preferences for attributes (or features) of goods, services or policy interventions. It assumes that any good or service (in this case models of care for fibromyalgia) can be described by its attributes and the measure (or 'levels') of these attributes. Each respondent faces a series of hypothetical scenarios (choice sets) composed of two or more alternatives. In each choice set, respondents are asked to choose their preferred scenario. The principle underlying a DCE is choices are made based on the features (or attributes) of different actions. Therefore, a DCE enables researchers to gain insight into the relative importance of each attribute, and the trade-offs between attributes.

This study is a survey of participants identified from a previous study about chronic widespread pain ("MAintaining MusculOskeleTal Health" - MAmMOTH). As part of the MAmMOTH study, a randomly selected sample of adults aged 25 years and over registered with participating general practices in Scotland were mailed a screening questionnaire. All individuals who returned the completed screening questionnaire and who met some criteria for fibromyalgia and consented to be contacted for future health survey research were approached for a further survey, the DEHLTA study. The DEHLTA survey questionnaire asked participants if they had ever received a diagnosis of fibromyalgia. From respondents to the DEHLTA study, individuals who said they had a diagnosis of fibromyalgia and who consented to be contacted for future studies will be eligible to participate in the current pilot study. We estimate this will be approximately 80 individuals.

Inclusion criteria are:

  • Reporting a diagnosis of fibromyalgia in the DEHLTA survey
  • Consenting to be contacted for future health survey research in the DEHLTA survey

Exclusion criteria are:

  • Not reporting a diagnosis of fibromyalgia in the DEHLTA survey
  • Not consenting to be contacted for future health survey research in the DEHLTA survey

Eligible individuals will receive a one-off paper questionnaire (including an invitation letter, a patient information sheet, and a prepaid, preaddressed envelope) and be invited to participate in the current study. A reminder letter will be mailed two weeks later. Mailings will be carried out by study staff at the University of Aberdeen.

We will analyse the feasibility of the model of data collection and quality of the questionnaire responses by estimating response rate, questionnaire completion times, item response and qualitative feedback on question items. In addition, we will assess frequencies and associations in choice responses to examine the strength of preferences relating to service provision in terms of the specified attributes (time to diagnosis, diagnosis provider, treatment type, waiting time, and type of on-going help and support). The data analysis conducted will inform the design of a larger study involving participants from a national patient organisation.

02

Conditions studied

03

In context

Fibromyalgia

1,335 studies on the registry are indexed under Fibromyalgia; 265 are open to participants now.

This study's enrollment of 41 is below the median of 100 across 270 observational studies indexed under Fibromyalgia.

Browse Fibromyalgia studies →

Lead sponsor

University of Aberdeen is the lead sponsor of 170 studies on the registry; 23 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Respondents to a previous survey questionnaire who had told us they had a diagnosis of fibromyalgia

Inclusion criteria

  • Reporting a diagnosis of fibromyalgia in the DEHLTA survey
  • Consenting to be contacted for future health survey research in the DEHLTA survey

Exclusion criteria

Exclusion Criteria:

  • Not reporting a diagnosis of fibromyalgia in the DEHLTA survey
  • Not consenting to be contacted for future health survey research in the DEHLTA survey
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
41 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Patient Preferences for treatment for fibromyalgia

    This will be derived from the participants' answers to discrete choice questions

    Time frame: The outcome will be measured at a single timepoint, i.e. the time of completion of the survey questionnaire. The survey will be carried out during August and September 2021.

07

Study locations

1 site
  • University of Aberdeen
    Aberdeen, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05053464
Lead sponsor
University of Aberdeen
Responsible party
Sponsor
First posted
Sep 22, 2021
Start date
Aug 25, 2021
Primary completion
Oct 8, 2021
Completion
Oct 8, 2021
Last update
May 23, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion